Hims & Hers shares tumble as FDA resolves obesity drug shortage

Hims & Hers Health shares fell 15% after the FDA resolved tirzepatide injection shortage, affecting the market for obesity drugs and compounded offerings.

Morgan Stanley starts Hims & Hers at ‘overweight,’ on strong revenue growth

Morgan Stanley gave Hims Hers Health an 'overweight' rating with a $42 target, forecasting strong revenue growth and highlighting its entry into GLP-1 weight loss treatments.

Ro partners with Eli Lilly to enhance obesity treatment access; Hims & Hers Health shares fall

Ro collaborates with Eli Lilly to facilitate access to Zepbound obesity medication through LillyDirect, enhancing patient experience and streamlining medication delivery.

Hims & Hers Health gain on potential FDA leadership ties

Amazon's push into telehealth knocks shares of Hims & Hers

Hims & Hers stock falls as Amazon launches Telehealth offering

Hims & Hers stock dropped 15% after Amazon announced new telehealth services for Prime members, creating potential competition for its subscription-based health offerings.

Earnings call: Hims & Hers reports robust Q3 growth, plans for expansion

After-hours movers: Palantir, Cleveland-Cliffs, Coinbase and more

Palantir surged 12% post-earnings; NXP, Cleveland-Cliffs, Wynn, and Lattice dipped. Dollar Tree and Hims & Hers rose, while Coinbase fell after an executive share sale.

Hims & Hers Health Q3 earnings beat estimates, raises guidance

Hims Hers Health Inc. exceeds Q3 earnings expectations, raises full-year guidance, and reports 44% YoY subscriber growth, highlighting profitability and strong future revenue projections.

Hims & Hers stock target raised at BofA on upside to consensus

Bank of America increased Hims & Hers Health's price target, noting strong sales trends despite growth deceleration and projected revenue upside for Q3, highlighting resilience and digital engagement.